WORK Medical Technology (WOK) regains Nasdaq $1.00 bid compliance

WORK Medical Technology Group LTD reported it has regained compliance with Nasdaq’s Minimum Bid Price Requirement.

Accepted by SEC EDGAR 11/07/2025 - 04:30 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

WORK Medical Technology Group LTD reported it has regained compliance with Nasdaq’s Minimum Bid Price Requirement. Nasdaq confirmed the company maintained a closing bid of $1.00 or greater per Class A ordinary share for 10 consecutive business days, from October 10, 2025 to November 3, 2025.

Nasdaq notified the company on November 4, 2025 that the matter is closed. This follows earlier notices granting time through April 6, 2026 to cure the deficiency under Listing Rule 5550(a)(2).

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did WOK announce in its Form 6-K?

The company regained compliance with Nasdaq’s Minimum Bid Price Requirement after maintaining a closing bid of $1.00 or greater for 10 consecutive business days.

What is Nasdaq’s Minimum Bid Price Requirement for WOK?

Nasdaq Listing Rule 5550(a)(2) requires a minimum bid price of $1.00 per share for the company’s Class A ordinary shares.

Over what period did WOK meet the $1.00 bid price standard?

From October 10, 2025 to November 3, 2025, covering 10 consecutive business days.

When did Nasdaq confirm WOK’s compliance?

Nasdaq sent a confirmation letter on November 4, 2025, stating the matter is closed.

What prior compliance timeline applied to WOK?

After an initial cure period through October 6, 2025, Nasdaq provided an additional 180 days through April 6, 2026 to regain compliance.

Which shares are subject to the requirement?

The company’s Class A ordinary shares, par value $0.0005 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission File Number: 001-42256

WORK Medical Technology Group LTD

Floor 23, No. 2 Tonghuinan Road

Xiaoshan District, Hangzhou City, Zhejiang Province

The People’s Republic of China

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒          Form 40-F ☐

WORK Medical Technology Group LTD Regains Compliance with Nasdaq Minimum Bid Price Requirement

As previously disclosed, on April 7, 2025, WORK Medical Technology Group LTD (the “Company”) received a deficiency letter from The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”), because, for a period of 30 consecutive business days, the Company’s Class A ordinary shares, par value $0.0005 per share (“Class A Ordinary Shares”), failed to maintain a minimum bid price of $1.00 per Class A Ordinary Share. According to Nasdaq Listing Rule 5810(c)(3)(A), the Company was given an initial period of 180 calendar days, or until October 6, 2025, to regain compliance with the Minimum Bid Price Requirement. Subsequently, on October 7, 2025, the Company was provided an additional 180-day calendar days, or until April 6, 2026, to regain compliance.

On November 4, 2025, the Company received a letter from Nasdaq stating that the Company has regained compliance with the Minimum Bid Price Requirement by maintaining a minimum closing bid price of the Class A Ordinary Shares of $1.00 or greater per Class A Ordinary Share for the last 10 consecutive business days, from October 10, 2025 to November 3, 2025, and that this matter is now closed.

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: November 7, 2025

	WORK Medical Technology Group LTD
	By:	/s/ Shuang Wu
	Name:	Shuang Wu
	Title:	Chief Executive Officer and Chairman of the Board of Directors

2